Core Viewpoint - Heng Rui Medicine announced the approval of clinical trials for SHR-3045 injection, a self-developed biological product aimed at treating rheumatoid arthritis by inhibiting immune cell function and reducing inflammation [1] Group 1 - The company received the clinical trial approval notice from the National Medical Products Administration for SHR-3045 injection [1] - SHR-3045 is expected to improve clinical symptoms in the treatment of rheumatoid arthritis [1] - The clinical trials are set to commence in the near future [1]